The clinical team at the RVC…
Boehringer Ingelheim has released details of research presented at the 29th World Veterinary Congress which shows dogs with congestive heart failure (CHF) due to myxomatous mitral valve disease (MMVD) live longer when treated with pimobendan (Vetmedin®) compared…
Boehringer Ingelheim has announced the results of an independent three-year study which demonstrates that dogs suffering from the most common type of heart failure lived longer (average time in the study of 267 days vs. 140 days) when treated with the…
Veterinary surgeons are being called on to help recruit dogs for a clinical study called EPIC - the Evaluation of Pimobendan In dogs with Cardiomegaly caused by pre-clinical mitral valve disease (MVD).
The long-term study, which is supported by Boehringer…
The RVC has published the results of a study which showed that dogs treated with pimobendan at the preclinical stage of mitral valve disease (MVD) remained asymptomatic for an average 15 months longer and lived for significantly longer than the placebo…
Sylvie, a four-month-old Maine Coon, was referred…
Davies says pulmonic…
The Mercury Challenge, which is being conducted by Ceva…
Davies says its Cardiac Electrophysiology Laboratory, headed by Pedro Oliveira (pictured…
Lottie, an 11-month-old Labrador puppy was found to have a very…
The survey of 1,019 dog owners was conducted…
The collection…